Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jennifer L. Good
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Beta
- 1.07
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 168.79
Financials
Net Income
$-17.80MEBITDA
$-17.82MFree Cash Flow
$-17.55MEPS (diluted)
$-0.11Shares Outstanding (diluted)
156.60M+1147.6%Operating Expenses
$20.51MCash & Debt
$318.87MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-42.76M | $-0.29 |
| 2024 | $0.00 | $-47.91M | $-0.47 |
| 2023 | $0.00 | $-29.07M | $-0.29 |
| 2022 | $0.00 | $-29.15M | $-0.45 |
| 2021 | $0.00 | $-33.94M | $-1.49 |
| 2020 | $0.00 | $-32.76M | $-1.81 |
| 2019 | $0.00 | $-26.05M | $-1.46 |
| 2018 | $0.00 | $-20.55M | $-2.29 |
| 2017 | $0.00 | $-12.86M | $-1.43 |
| 2016 | $0.00 | $-11.09M | $-0.69 |
Valuation
TRVIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Neutral
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough
View source ↗ - Newsseekingalpha.com·6d ago·Neutral
…sion plans into non-IPF ILD and refractory chronic cough. Haduvio's positive Phase II data in both IPF and RCC, ongoing pivotal trials, and robust liquidity underpin TRVI's transition to a specialty pharma platform. TRVI's specialty-first strategy targets concentrated pulmonology networks, enabling efficient market entry and future expansion without large-scale commercial buildout.
View source ↗
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise +10.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.11 vs $-0.11miss
- Tue, May 5$-0.09 vs $-0.07miss
- Tue, Mar 17$-0.06 vs $-0.10beat
- Thu, Nov 13$-0.08 vs $-0.10beat
- Thu, Aug 7$-0.09 vs $-0.10beat
- Thu, May 8$-0.09 vs $-0.13beat
Estimates and results for TRVI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TRVI officers and directors.
- Bought
- —
- Sold
- $939k
0 trades
14 trades
- Sciascia Thomassold
- Good Jennifer Lsold
- Simon Farrellsold
- Simon Farrellsold
- Good Jennifer Lsold
- Good Jennifer Lsold
- Good Jennifer Lsold
- Good Jennifer Lsold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.